Measures for Adverse Events and Outpatient Chemotherapy of S-1+Cisplatin for Unresectable Progressive Recurrent Gastric Cancer

Abstract

Although S-1+cisplatin therapy is used as first-line therapy for unresectable progressive/recurrent gastric cancer, the incidence of adverse events is not low. Renal dysfunction, especially, is an important side effect of dose-limiting toxicity and requires caution. Conversely, outpatient chemotherapy is becoming popular nationwide, but at the time of cisplatin administration, it is burdensome for patients to be infused for hospitalization to prevent renal dysfunction. It is possible that there is no difference between the incidence of renal dysfunction in patients to whom cisplatin is administered during hospitalization and that in outpatients treated with a short hydration regimen. Furthermore, currently, because of the increase in the infusion speed and use of magnesium, data on renal dysfunction associated with cisplatin administration in outpatient settings have not been reported. Here we report a case of the onset of renal dysfunction.